Gland Pharma Ltd (GLAND) Financials - Quarterly Results, Profit & Loss, Balance Sheet, Cash Flow Gland Pharma Ltd reported sales of ₹1,800 Cr, operating profit of ₹489 Cr (OPM 27%) and net profit of ₹317 Cr for the quarter ended Jun 2026. Figures in ₹ crore, consolidated where available.
GLAND quarterly results (₹ Cr) Metric Sep 2024 Dec 2024 Mar 2025 Jun 2025 Sep 2025 Dec 2025 Mar 2026 Jun 2026 Sales 1,406 1,384 1,425 1,506 1,487 1,695 1,743 1,800 Expenses 1,109 1,024 1,077 1,138 1,173 1,260 1,230 1,311 Operating Profit 297 360 348 368 314 435 513 489 OPM 21% 26% 24% 24% 21% 26% 29% 27% Other Income 60 58 44 58 84 39 111 61 Interest 6 23 7 12 8 4 10 4 Depreciation 94 96 96 101 106 108 109 111 Profit before tax 257 299 288 313 284 362 506 435 Tax 36% 32% 35% 31% 35% 28% 28% 27% Net Profit 164 205 187 215 184 261 367 317 EPS in Rs 9.93 12.42 11.32 13.08 11.15 15.87 22.26 19.21
GLAND profit & loss, annual (₹ Cr) Metric Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 TTM Sales 4,401 3,625 5,665 5,616 6,431 6,725 Expenses 2,890 2,600 4,332 4,348 4,801 4,974 Operating Profit 1,510 1,025 1,333 1,269 1,630 1,751 OPM 34% 28% 24% 23% 25% 26% Other Income 224 184 170 214 292 296 Interest 5 7 26 42 33 26 Depreciation 110 147 345 378 424 434 Profit before tax 1,619 1,055 1,133 1,063 1,465 1,587 Tax 25% 26% 32% 34% 30% - Net Profit 1,212 781 772 699 1,027 1,129 EPS in Rs 73.75 47.42 46.9 42.4 62.35 68.49 Dividend Payout 0% 0% 43% 42% 32% -
GLAND balance sheet (₹ Cr) Metric Mar 2023 Mar 2024 Mar 2025 Sep 2025 Mar 2026 Equity Capital 16 16 16 16 16 Reserves 7,942 8,707 9,134 9,546 10,341 Borrowings 4 372 314 302 284 Other Liabilities 814 1,515 1,708 1,935 1,807 Total Liabilities 8,778 10,611 11,173 11,800 12,449 Fixed Assets 1,571 3,947 4,147 4,403 4,492 CWIP 177 238 151 209 342 Investments 0 0 0 0 0 Other Assets 7,030 6,426 6,875 7,188 7,614 Total Assets 8,778 10,611 11,173 11,800 12,449
GLAND cash flows (₹ Cr) Metric Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Cash from Operating Activity 791 364 997 915 1,031 Cash from Investing Activity -999 1,211 -1,749 1,718 188 Cash from Financing Activity 35 15 -799 -433 -417 Net Cash Flow -174 1,590 -1,552 2,199 803 Free Cash Flow 269 141 599 521 538 CFO/OP 79% 66% 98% 100% 91%
GLAND ratios Metric Mar 2022 Mar 2023 Mar 2024 Mar 2025 Mar 2026 Debtor Days 99 88 100 99 107 Inventory Days 205 421 278 294 284 Days Payable 80 127 129 143 136 Cash Conversion Cycle 225 382 250 250 255 Working Capital Days 168 242 155 173 145 ROCE 25% 15% 14% 12% 15%